A safety review of the first three Alzheimer's disease patients given NsGene's nerve-growth-factor secreting encapsulated cells has been favourable, and a further three patients have now be included in the Phase Ib clinical trial.
The private Danish company is evaluating its novel implant, which consists of a hollow-fibre semipermeable membrane containing human nerve cells...